Moxidectin FDA Approval History
Last updated by Judith Stewart, BPharm on May 12, 2025.
FDA Approved: Yes (First approved June 13, 2018)
Generic name: moxidectin
Dosage form: Tablets
Company: Medicines Development for Global Health
Treatment for: Onchocerciasis, River Blindness
Moxidectin is an anthelmintic indicated for the treatment of onchocerciasis due to Onchocerca volvulus in adults and pediatric patients aged 4 years and older and weighing at least 13 kg.
Development timeline for moxidectin
| Date | Article |
|---|---|
| Feb 20, 2025 | Approval U.S. FDA Expands Indication for Moxidectin to Treat River Blindness in Children as Young as Four |
| Jun 13, 2018 | Approval FDA Approves Moxidectin for the Treatment of River Blindness |
See also
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.